Loading cancer entity…
Loading cancer entity…
Clinical trials
4,033 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (699)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06439966 | Expanded Access to ABBV-787 | no longer available | — | — | AbbVieINDUSTRY | 0 | Feb 12, 2026 | clinicaltrials |
| NCT05269771 | MAP to Provide Access to Ruxolitinib, for Patients With Polycythemia Vera | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 8 | Nov 5, 2025 | clinicaltrials |
| NCT03420430 |
| Expanded Access to Provide GL-ONC1 for the Treatment of Advanced Cancers With No Standard of Care |
| no longer available |
| — |
| — |
| Genelux CorporationINDUSTRY |
| 1 |
| Sep 25, 2024 |
| clinicaltrials |
| NCT05219266 | Managed Access Programs for PKC412, Midostaurin | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Jun 28, 2024 | clinicaltrials |
| NCT03592576 | Expanded Access to Navitoclax | no longer available | — | — | AbbVieINDUSTRY | 0 | May 6, 2024 | clinicaltrials |
| NCT04518644 | Nilotinib, for Patients With CML-CP or CML-AP | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 0 | Apr 28, 2023 | clinicaltrials |
| NCT04678466 | Flotetuzumab Expanded Access Program | no longer available | — | — | MacroGenicsINDUSTRY | 0 | May 31, 2022 | clinicaltrials |
| NCT02258490 | Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation | no longer available | — | — | Emory UniversityOTHER | 1 | Mar 15, 2022 | clinicaltrials |
| NCT01200017 | Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant | no longer available | — | — | Christopher DvorakOTHER | 1 | May 27, 2021 | clinicaltrials |
| NCT03723057 | Expanded Access for AG-221 | no longer available | — | — | CelgeneINDUSTRY | 1 | Oct 24, 2019 | clinicaltrials |
| NCT03409081 | Early Access Program (EAP) of Gilteritinib (ASP2215) in Patients With FMS-like Tyrosine Kinase 3 (FLT3) Mutated Relapsed or Refractory Acute Myeloid Leukemia (AML) or With FLT3-Mutated AML in Complete Remission (CR) With Minimal Residual Disease (MRD) | no longer available | — | — | Astellas Pharma Global Development, Inc.INDUSTRY | 3 | Sep 13, 2018 | clinicaltrials |
| NCT01549548 | Compassionate Use Ponatinib | no longer available | — | — | OHSU Knight Cancer InstituteOTHER | 1 | Mar 15, 2013 | clinicaltrials |
| NCT00302016 | Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 34 | Aug 26, 2011 | clinicaltrials |
| NCT00413270 | Oral Nilotinib in Adults With Chronic Myeloid Leukemia (CML) in Blast Crisis Who Are Imatinib Resistant or Intolerant | no longer available | — | — | Novartis PharmaceuticalsINDUSTRY | 1 | Jul 13, 2011 | clinicaltrials |
Data updated 22 days agoSource updated Feb 12, 2026source: clinicaltrials